Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. CATX has several positive signals and is within a rising trend, so we believe it will perform strongly in the next couple of days or weeks. We therefore hold a positive evaluation of this stock. Our analysis conclusion for this stock is a Strong Buy candidate.
CATX stock price ended at $3.45 on Wednesday, after losing-2.27%
The Perspective Therapeutics Inc stock price decreased by -2.27% on the last trading day (18 Jun 2025), dropping from 3.56 to 3.45. Throughout the last trading session, the stock experienced a fluctuation of 5.83% , ranging from a day low of $3.43 to a day high of 3.63. The price has declined in 7 of the last 10 days, resulting in a total change of 10.22% during this period. On the last day, trading volume decrease by -323.37K shares, with the falling prices. This could serve as an early warning, indicating that risk may slightly increase in the coming days. In total, 784.41K shares were traded, amounting to approximately 2.74M.
CATX Technical Signals
CATX(Perspective Therapeutics Inc Corp) has 3 buy signals and 2 sell signals now. The current trend is downtrend starting from 2025-06-10. The total price change during this trend is +0.58%. Recently, the price has decreased but the volume has also decreased, indicating a potential rebound signal. The average turnover of CATX over the last 5 trading days is 3.67M. Overall, the technical indicator signals lean more toward a Neutral outlook in the mid-term.
CATX Moving Average Analysis
Perspective Therapeutics Inc's overall moving average trend leans more bullish as of Friday, June 20, 2025, with 1 negative signals and 3 positive signal. In the mid-term, the SMA_20 being above the SMA_60 signals a strong bullish trend. There will be some resistance from the lines at $3.8559133333333335, and $4.165333333333334. A break-up above any of these levels will issue buy signals. There will be some support from the lines at $2.854753333333334, and $2.5453333333333337. A break-down below any of these levels will issue sell signals.
CATX Short Selling Analysis
The short sale ratio of Perspective Therapeutics Inc(CATX) as of 17 Jun 2025 is 13.55%, dropping from last trading day. With decreasing price from 3.61 to 3.53. The short sell activity indicate that short sellers may be anticipating price hit a bottom.
Technical Signal
Technical Signals Summary
Sell
2
Buy
3
Moving Average
Swing
Positive
Stock Price Above SMA_5
Short Term
Positive
SMA_5 Above SMA_20
Mid Term
Positive
SMA_20 Above SMA_60
Long Term
Negative
SMA_60 Below SMA_200
Short Selling
Close Price
Short Sale Ratio
Short Sale Volume
3 Bullish Signals
3 Bullish Signals
When Value satisfies Signal, Indicator signals Bullish
Indicators
Signal
Value
Meaning
Awesome Oscillator (5, 34)
AO_5_34 > 0
0.591
Bullish
Momentum (10 days)
MOM_10 > 0
0.32
Bullish
Moving Average Convergence Divergence (12, 26, 9)
MACD_12_26_9 > 0
0.267
Bullish
2 Bearish Signals
2 Bearish Signals
When Value satisfies Signal, Indicator signals Bearish
Indicators
Signal
Value
Meaning
Stochastic Oscillator %K (14, 3, 3)
STOCHk_14_3_3 > 80
84.741
Bearish
Stochastic RSI %K (14, 14, 3, 3)
STOCHRSIk_14_14_3_3 > 80
86.625
Bearish
CATX Price Prediction & Forecast by Similar Chart Analysis
Based on historical patterns and backtesting of stocks with similar movements to Perspective Therapeutics Inc(CATX), our algorithm predicts CATX's 1-month price at $2.96, with an -6.47%downwardshift. Using a similarity score up to 95.87%and other factors, This forecast updates weekly, adjusting for significant deviations.
Similar Chart
The price prediction chart for Perspective Therapeutics Inc (CATX.A) stock, as of Sunday, June 15, 2025 , forecasts a -6.47% change over the next month, based on its high correlation with FL.N stock patterns. The similarity between their price movements over the analyzed periods is 95.87%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
CATX
No Data
FL
Down: -6.47%Similarity: 95.87%
Name
Similarity
Up/Down
FL.N
95.87%
-6.47%
SRCE.O
95.80%
+1.21%
BAFN.O
95.63%
+11.42%
BILI.O
95.51%
+38.73%
RIME.O
95.41%
-10.17%
WOLF.N
95.41%
-9.33%
SPSC.O
95.40%
-14.75%
NHC.A
95.32%
-0.18%
SUPV.N
95.29%
+40.48%
SHOP.N
95.20%
+17.85%
CATX Seasonality Analysis
Based on CATX's historical stock price data across all years, the probability of a positive return in June is36.36%, suggesting it maynotbe an ideal month to invest in CATX. In contrast,Januaryoffers the highest probability of positive returns at72.73%, making it a potentially strong month for investment.
However, this is only a prediction based on one method, and a comprehensive assessment of the stock's future trend should consider additional factors. Our final stock price commentary incorporates three main evaluation dimensions: technical signals, Moving Average trends, and similar chart pattern matching, with the first two dimensions carrying the primary weight to ensure a more robust and accurate forecast.
Monthly Seasonality
The radar chart shows that buying Perspective Therapeutics Inc (CATX.A) stock in January has the highest probability of a positive return (72.73%), while September has the lowest probability (10.00%).
Performance Seasonality
The chart shows Perspective Therapeutics Inc. (CATX)'s annual stock price return for the past three years, helping you analyze price trends and identify recurring trends on an annual basis.
People Also Watch
FAQ
Should I buy Perspective Therapeutics Inc (CATX.A) stock?
Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. CATX has several positive signals and is within a rising trend, so we believe it will perform strongly in the next couple of days or weeks. We therefore hold a positive evaluation of this stock. Our analysis conclusion for this stock is a Strong Buy candidate.
Which months have the highest win rate for buying Perspective Therapeutics Inc (CATX.A) stock in a year?
The radar chart shows that buying Perspective Therapeutics Inc (CATX.A) stock in January has the highest probability of a positive return (72.73%), while September has the lowest probability (10.00%).
How has Perspective Therapeutics Inc. (CATX)'s stock price performed over the past three years?
CATX's stock price rose by 66.67% in 2023,decreased by -20.25% in 2024, and went up by 4.23% in 2025.
Is CATX a buy based on overall technical signals summary?
CATX has 3 buy signals and 2 sell signals now. Overall the technical rating for CATX is Neutral . Note that market conditions change all the time. In addition to technical ratings, keep an eye on the Valuation Level of CATX.
What is the trend of Perspective Therapeutics Inc (CATX)'s moving average?
Perspective Therapeutics Inc's overall moving average trend leans more bullish as of June 20 2025, with 1 negative signals and 3 positive signal.
What is price prediction for CATX stock next month?
The price prediction chart for Perspective Therapeutics Inc (CATX.A) stock, as of June 15 2025, forecasts a -6.47% change over the next month, based on its high correlation with FL stock patterns. The similarity between their price movements over the analyzed periods is 95.87%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
What is price prediction 2025 for CATX Stock?
The price prediction for CATX stock in 2025 is $3.20, driven by positive clinical trial results and strong analyst sentiment. The stock may drop to $2.00 if earnings disappoint. Current technical indicators suggest moderate bullish momentum.
What is price prediction 2030 for CATX Stock?
The price prediction for CATX stock by 2030 is $20 per share. This forecast is based on the company's promising clinical trial results, including positive interim data from its Phase 1/2a trial forVMT-α-NET, which showed favorable safety and efficacy in treating neuroendocrine tumors. Additionally, CATX's strategic pipeline expansion with PSV359 targeting FAP-α expressing solid tumors positions it for potential long-term growth in the oncology market.